Northern Antibiotics Presents New Data On Novel Polymyxin Compounds At The Joint ICAAC/IDSA 2008

Northern Antibiotics Ltd., the developer of novel polymyxin derivatives for the treatment of infections caused by multidrug-resistant Gram-negative bacteria, revealed animal efficacy and pharmacokinetic data from their NAB compounds at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC. Northern Antibiotics has developed two series of novel polymyxin (NAB) compounds (Vaara M. et al., 2008, Antimicrob. Agents Chemother.

More: continued here

Filed under: Clinical Trials on October 29th, 2008